Dernière minute
DEGroßbrände nach ukrainischen Angriffen in RusslandDESchweres Erdbeben in Kolumbien: Mindestens 111 Tote und Notstand ausgerufenDEUS-Präsident Trump: Minen in der gesamten Straße von Hormus geräumtDEExplosive Drohne am Flughafen Leipzig: Neues Bedrohungsszenario für BundesinnenministerDETrump soll heimlich in Militärflieger geschmuggelt worden sein – Morddrohung als GrundDEAndrás Baka zum ungarischen Staatspräsidenten gewähltDERamelow plädiert für CDU-Linke-Kooperation in Sachsen-AnhaltDEÜber 2.000 Tote bei Ebola-Ausbruch im KongoDESüdkorea nimmt zwei chinesische Staatsbürger wegen Spionageverdachts festDESyriens Ex-Diktator Assad in Abwesenheit zum Tode verurteiltDEGroßbrände nach ukrainischen Angriffen in RusslandDESchweres Erdbeben in Kolumbien: Mindestens 111 Tote und Notstand ausgerufenDEUS-Präsident Trump: Minen in der gesamten Straße von Hormus geräumtDEExplosive Drohne am Flughafen Leipzig: Neues Bedrohungsszenario für BundesinnenministerDETrump soll heimlich in Militärflieger geschmuggelt worden sein – Morddrohung als GrundDEAndrás Baka zum ungarischen Staatspräsidenten gewähltDERamelow plädiert für CDU-Linke-Kooperation in Sachsen-AnhaltDEÜber 2.000 Tote bei Ebola-Ausbruch im KongoDESüdkorea nimmt zwei chinesische Staatsbürger wegen Spionageverdachts festDESyriens Ex-Diktator Assad in Abwesenheit zum Tode verurteilt
Newsgather

biologics

Stable13 articles4 sourcesDernière mise à jour: 20/07/2026
Sujets associéssamsung biologicsstrikesouth koreabiotechSamsung Biologicsunionlabor disputecollective bargaining

Derniers articles

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Expand Peptide Therapeutics
En développement
Business·20/07/2026Résumé IA

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Expand Peptide Therapeutics

South Korea's Samsung Biologics made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland's PolyPeptide Group. This acquisition, the largest biopharma M&A in South Korea's history, aims to diversify Samsung's portfolio into fast-growing peptide therapeutics, including obesity treatments, and expand its global footprint.

C
CNBC World
1 min de lecture
Samsung Biologics Union Agrees to Return to Negotiation Table After First-Ever Strike
En développement
Labor·03/05/2026Résumé IA

Samsung Biologics Union Agrees to Return to Negotiation Table After First-Ever Strike

Samsung Biologics union has agreed to return to negotiations on Monday under labor ministry mediation, after its first-ever strike entered day three. The union demands a 14% increase in base and performance pay, a 30 million won one-off cash incentive, and bonuses equal to 20% of annual operating profit. The company has proposed 6.2% and claims the walkout could cause at least 640 billion won in damage, equivalent to half its Q1 sales.

Y
Yonhap News
2 min de lecture
Samsung Biologics Union Agrees to Return to Negotiation Table After First-Ever Strike
En développement
Labor·03/05/2026Résumé IA

Samsung Biologics Union Agrees to Return to Negotiation Table After First-Ever Strike

Samsung Biologics union has agreed to return to negotiations on Monday under labor ministry mediation, after the first round of talks failed. The strike, the first in the company's history, is now in its third day with around 2,800 of 4,000 unionized workers walking out. The union demands a 14% increase in base and performance pay, a 30 million won one-off cash incentive per worker, and bonuses equal to 20% of annual operating profit. The company has proposed a 6.2% combined increase and claims the strike could cause at least 640 billion won in damage, equivalent to roughly half of its first-quarter sales.

Y
Yonhap News
1 min de lecture
ByteDance’s drug unit presents AI-designed therapies at global conferences
ACTU
02/05/2026

ByteDance’s drug unit presents AI-designed therapies at global conferences

ByteDance, the Chinese owner of TikTok, is pushing deeper into artificial intelligence with Anew Labs, a drug-discovery unit that has begun presenting its AI-designed therapies at international conferences. The unit – also known as Anew Therapeutics or ByteDance AI Drug Discovery – operates from Shanghai, Singapore and San Jose, California. Its official website listed 36 core members, as well as big names on its “scientific advisory board”: Liu Yongjun, former president of Innovent Biologics, Ji...

S
SCMP Economy
Samsung Biologics Workers Begin First-Ever Strike, Company Warns of Potential $433M Losses
En développement
Business·01/05/2026Résumé IA

Samsung Biologics Workers Begin First-Ever Strike, Company Warns of Potential $433M Losses

Unionized workers at Samsung Biologics began a five-day general strike on May 1, marking the first labor action since the company's 2011 establishment. The union demands a 14% increase in base and performance pay, a 30 million won cash incentive, and bonuses equal to 20% of annual operating profit. The company proposed 6.2% and warned that full-scale strike losses could exceed 640 billion won ($433 million), roughly half of its Q1 sales. The strike has already forced cessation of some batch production of anticancer and HIV treatments, with current losses estimated at 150 billion won.

Y
Yonhap News
2 min de lecture
Samsung Biologics Workers Begin First-Ever Strike Over Wage Demands
En développement
Business·01/05/2026Résumé IA

Samsung Biologics Workers Begin First-Ever Strike Over Wage Demands

Unionized workers at Samsung Biologics launched a five-day general strike on May 1, 2026, marking the first labor walkout in the company's history since its 2011 establishment. The union demands a 14% increase in base and performance-related pay, a 30 million won one-off cash incentive, and bonuses equal to 20% of annual operating profit. The company has proposed 6.2% and warns losses could exceed 640 billion won ($433 million). Negotiations failed after 13 rounds despite a court injunction attempt.

Y
Yonhap News
1 min de lecture